Session » Abstracts: Immunological Complications of Medical Therapy (1728–1733)
- 10:00AM-10:15AM
-
Abstract Number: 1728
Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
- 10:15AM-10:30AM
-
Abstract Number: 1729
The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
- 10:30AM-10:45AM
-
Abstract Number: 1730
Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
- 10:45AM-11:00AM
-
Abstract Number: 1731
A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
- 11:00AM-11:15AM
-
Abstract Number: 1732
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
- 11:15AM-11:30AM
-
Abstract Number: 1733
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations